Zhang, Q., Zhang, Q., Liu, X., Liu, X., Wei, S., Zhang, L., . . . Yan, S. (2021). Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Frontiers Media S.A.
Chicago Style (17th ed.) CitationZhang, Qiyi, et al. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Frontiers Media S.A, 2021.
MLA (8th ed.) CitationZhang, Qiyi, et al. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Frontiers Media S.A, 2021.
Warning: These citations may not always be 100% accurate.